Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO,Calif.,SUZHOU and SHANGHAI,China,May 19,2022 -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"),a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:

BTIG China Biotech Day (Virtual)

Fireside chat: June 1

One-on-one meetings: June 1

To listen to the live event,please contact your BTIG representative.

Jefferies Healthcare Conference

Fireside chat: June 10 at 9:00 a.m. Eastern Time

One-on-one meetings: June 8-10

Location: New York,NY

Webcast Link:https://ir.gracellbio.com/news-events/events-and-presentations

The replay of the fireside chat can be accessed through the "News and Events" section of Gracell's investor website.

Citi 3rd Pan-Asia Regional Investor Conference (Virtual)

One-on-one and small group meetings: June 8-10

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module,Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies,including lengthy manufacturing time,suboptimal cell quality,high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell,please visit www.gracellbio.com.Follow @GracellBio onLinkedIn.

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com